8-K: Strata Critical Medical Q4 2025 Revenue Soars 83.5%, Raises 2026 Guidance

Strata Critical Medical announced strong fourth quarter 2025 results with an 83.5% year-over-year revenue increase and raised its full year 2026 financial guidance.

Summary

• Total revenue for Q4 2025 increased 83.5% year-over-year to $66.8 million.
• Logistics revenue, representing organic growth, increased 35.3% year-over-year in Q4 2025 to $49.2 million.
• Full year 2025 revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both exceeding the high end of previous guidance.
• Net loss from continuing operations decreased by 27.5% year-over-year in Q4 2025 to $(5.4) million.
• Adjusted EBITDA for Q4 2025 increased 547.0% year-over-year to $7.0 million.
• Raised full year 2026 revenue guidance to between $260 million and $275 million (previously $255-$270 million).
• Raised full year 2026 Adjusted EBITDA guidance to between $29 million and $33 million (previously $28-$32 million).
• Ended FY 2025 with $61.2 million in cash and short-term investments.
• Acquired one additional aircraft in early 2026 to support customer wins in new geographies, expected to launch mid-year.
• Closed a $30 million asset-backed credit facility with JP Morgan, which is undrawn and can be increased to $50 million.
• Dr. Scott Silvestry assumed an expanded role as Chief Medical Officer to oversee clinical excellence.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong organic growth, successful acquisition integration, exceeding guidance, and raising future outlook, despite continued net losses.

Positives

• Q4 2025 total revenue increased 83.5% year-over-year to $66.8 million.
• Logistics revenue (organic growth) increased 35.3% year-over-year in Q4 2025, significantly ahead of targets.
• Logistics gross profit increased 39.5% year-over-year to $10.6 million in Q4 2025.
• Total gross profit increased 90.0% to $14.4 million in Q4 2025.
• Gross margin improved by 80 basis points year-over-year to 21.6% in Q4 2025.
• Full year 2025 revenue ($197.1 million) and Adjusted EBITDA ($14.1 million) both beat the high end of guidance.
• Net loss from continuing operations decreased by 27.5% year-over-year in Q4 2025 to $(5.4) million.
• Adjusted EBITDA increased 547.0% year-over-year to $7.0 million in Q4 2025.
• Raised full year 2026 revenue guidance to $260-$275 million (previously $255-$270 million).
• Raised full year 2026 Adjusted EBITDA guidance to $29-$33 million (previously $28-$32 million).
• Successful integration of the Keystone acquisition, contributing over 40% of sequential Logistics revenue growth in Q4 from Keystone's legacy customers.
• Secured a $30 million asset-backed credit facility with JP Morgan, expandable to $50 million, which is currently undrawn and attractively priced.
• Acquired an additional aircraft in early 2026 to support new customer wins and geographic expansion.
• Expanded Dr. Scott Silvestry's role to Chief Medical Officer, enhancing clinical excellence oversight.
• Strong position in the evolving regulatory environment with a customer base over-indexed to high-performing transplant centers and Organ Procurement Organizations.
• Management expects to maintain an average annualized Adjusted EBITDA growth rate of at least 30% over the coming years.

Negatives

• Full year 2025 net loss from continuing operations was $20.1 million, a 24.2% increase from $16.2 million in 2024.
• Operating loss from continuing operations increased 8.5% year-over-year in Q4 2025 to $(6.4) million.
• Operating cash flow was $(8.3) million in Q4 2025, significantly lower than Adjusted EBITDA due to $9.6 million in non-recurring items and a $5.7 million increase in working capital.
• Free Cash Flow from continuing operations, before aircraft and engine acquisitions, was $(8.7) million in Q4 2025.
• Selling, general and administrative expenses increased 46.9% in Q4 2025 and 19.7% for the full year 2025.
• Amortization of intangible assets increased 358.4% in Q4 2025 and 107.0% for the full year 2025, largely due to the Keystone acquisition.

Risks

• Continued net losses or failure to achieve or maintain profitability.
• Ability to realize the anticipated benefits of strategic transactions, including the divestment of the Passenger business and acquisition/integration of Keystone.
• Risks associated with future acquisitions or partnerships.
• Harm to reputation and brand, negative publicity, litigation, claims, or regulatory scrutiny.
• Ability to provide high-quality customer support and maintain trusted relationships with customers.
• Reliance on contractual relationships with transplant centers, hospitals, Organ Procurement Organizations, and strategic partners.
• Adoption and effective utilization of integrated clinical and logistics offerings by medical customers.
• Competition in the industry.
• Dependence on the availability and utilization of organ donors and transplant volumes.
• Insufficient reimbursement or funding for organ transport and related services.
• Inherent risks in organ transportation operations (air and ground).
• Advancements in preservation technology or alternative transport methods.
• Aviation safety risks.
• Effects of climate change, extreme weather events, or environmental developments affecting operations.
• Terrorist attacks, geopolitical conflict, or security events affecting aviation or healthcare infrastructure.
• Volatility in aircraft fuel availability or cost.
• Ability to obtain additional capital or financing.
• Restrictions under the credit agreement.
• Ability to manage growth.
• Insurance market conditions.
• Dependence on key personnel and ability to attract and retain qualified professionals.
• Employment-related claims, workforce litigation, or labor market challenges.
• Ability to maintain company culture during growth.
• Fluctuations in financial results and the non-comparability of historical financial statements.
• Risks associated with purchasing aircraft or evolving from an asset-light model.
• Risks associated with directly operating aircraft.
• Reliance on maintaining efficient aircraft utilization to manage costs, operating efficiency, and margins.
• Changes in regulatory frameworks.
• Reliance on third-party aircraft operators and the availability of sufficient third-party aircraft capacity.
• Workforce disruptions, operations interruptions, or financial difficulties affecting third-party operators or service workers.
• Risks arising from illegal, improper, or otherwise inappropriate operation of branded aircraft by third-party operators.
• Reliance on third-party cloud infrastructure, hosting providers, and other technology vendors.
• Interruptions, defects, failures, or vulnerabilities in technology systems or those of third-party providers.
• Cybersecurity incidents, data breaches, or misuse of artificial intelligence technologies.
• Ability to protect and enforce intellectual property rights.
• Risks associated with the use of open-source software.
• Operations within highly regulated environments.
• Impact of any litigation or regulatory investigations.
• Ability to comply with privacy, data protection, consumer protection, and security laws.
• Expansion of environmental regulations.
• Ability to remediate any material weaknesses and maintain effective disclosure controls and procedures.

Future Outlook

Strata Critical Medical is raising its full year 2026 revenue guidance to between $260 million and $275 million and Adjusted EBITDA guidance to between $29 million and $33 million. The company also expects free cash flow, before aircraft and engine acquisitions, to be between $15 million and $22 million for 2026. Management anticipates maintaining an average annualized Adjusted EBITDA growth rate of at least 30% over the coming years, driven by continued execution on acquisition opportunities and organic growth.

Management Comments

• "We continue to demonstrate our ability to achieve and exceed the ambitious goals we set for ourselves, both for organic growth, which at 35.3% this quarter was significantly ahead of our targets, as well as for our M&A platform." Will Heyburn, Co-CEO and CFO.
• "We're seeing smaller competitors proactively reach out, hoping to join forces which serves to enhance our already strong acquisition pipeline." Will Heyburn, Co-CEO and CFO.
• "We expect that our successful continued execution on these acquisition opportunities will significantly accelerate our growth trajectory, enabling us to maintain an average annualized Adjusted EBITDA growth rate of at least 30% over the coming years." Will Heyburn, Co-CEO and CFO.
• "We are set up for success in the evolving regulatory environment with a customer base over-indexed to high performing transplant centers and Organ Procurement Organizations that are being held up as the gold standard under new and proposed regulations." Melissa Tomkiel, Co-CEO and General Counsel.
• "Our acquisition of Keystone continues to bear fruit across the organization with more than 40% of our sequential Logistics revenue growth in Q4 generated from Keystone's legacy customers, demonstrating the value of our integrated, one-call offering." Melissa Tomkiel, Co-CEO and General Counsel.
• "We are at a pivotal moment in transplantation. New technologies and supportive regulatory frameworks are driving a significant increase in transplant volumes while steadily reducing the number of patients on waitlists." Dr. Scott Silvestry, Chief Medical Officer.

Industry Context

StockSavvy.ai notes that Strata Critical Medical's strong performance, particularly in its Logistics segment and the successful integration of Keystone, aligns with broader trends in the healthcare industry emphasizing efficiency, specialized logistics, and integrated service offerings for complex medical procedures like organ transplantation. The company's focus on high-performing transplant centers and Organ Procurement Organizations positions it well within an evolving regulatory environment that prioritizes efficiency and better utilization of medically complex organs, including those from Donation after Circulatory Death (DCD). The proactive M&A pipeline and ability to attract smaller competitors suggest a consolidating market where scale and specialized expertise are increasingly valued.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or projects with detailed results for direct comparison.
• StockSavvy.ai notes that Strata's organic logistics revenue growth of 35.3% year-over-year in Q4 2025 is robust, indicating strong market penetration and demand for its specialized services, potentially outpacing general healthcare logistics market growth which typically ranges in the high single to low double digits.
• The 547% year-over-year increase in Adjusted EBITDA for Q4 2025 and 274.5% for FY 2025, while partly driven by the Keystone acquisition, suggests significant operational leverage and successful integration, which would be considered strong performance relative to industry peers undergoing similar M&A activities.
• The company's stated goal of maintaining an average annualized Adjusted EBITDA growth rate of at least 30% over the coming years sets an ambitious benchmark, indicating confidence in its strategic direction and market position.

Management Changes

Corporate Governance

Legal Proceedings

• The Drulias lawsuit: Parties entered into a Stipulation of Settlement to fully resolve the matter in December 2025. Related costs were considered non-recurring.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, exceeding guidance, raised future outlook, and strategic acquisitions, potentially leading to increased share value.
• Employees: Positive impact from company growth, expansion into new geographies, and new hires (e.g., Surgical Director for Abdominal Organ Recovery), indicating job security and potential for career development.
• Customers (Transplant Centers, OPOs): Positive impact from enhanced service offerings, integrated 'one-call' solution, expanded regional network, and expertise in complex organ recovery (like DCD), leading to improved efficiency and better patient outcomes.
• Creditors (JP Morgan): Positive impact from the company securing a new credit facility, indicating access to capital and financial stability.

Next Steps

• Continue working diligently towards closing multiple acquisition opportunities currently under exclusivity in core competency areas.
• Launch new geographies mid-year 2026, supported by the additional aircraft acquired in early 2026.
• Continue building out an abdominal organ recovery platform with new hires.
• Conduct a conference call on March 3, 2026, to discuss results.

Key Dates

Recommendation

The company delivered exceptional Q4 2025 results, significantly exceeding revenue and Adjusted EBITDA guidance for the full year 2025. Organic growth in Logistics was robust at 35.3%, and the Keystone acquisition integration is proving highly successful, contributing substantially to sequential revenue growth. Management has confidently raised its 2026 guidance for both revenue and Adjusted EBITDA, projecting sustained high growth rates. The new undrawn credit facility provides ample liquidity for future M&A, and the expanded role of a Chief Medical Officer strengthens clinical oversight. Despite continued net losses, the strong operational performance, positive outlook, and strategic execution indicate a company poised for significant future value creation, making it a strong buy for investors.

Keywords

organ transport, medical logistics, transplant services, critical care, healthcare logistics, Adjusted EBITDA, revenue growth, Keystone acquisition, organ recovery, DCD, asset-backed credit facility, Q4 2025 earnings, 2026 guidance